Akero Therapeutics, Inc. Stock

Equities

AKRO

US00973Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
22.18 USD +1.56% Intraday chart for Akero Therapeutics, Inc. -4.48% -5.01%
Sales 2024 * - Sales 2025 * - Capitalization 1.53B
Net income 2024 * -235M Net income 2025 * -271M EV / Sales 2024 * -
Net cash position 2024 * 388M Net cash position 2025 * 282M EV / Sales 2025 * -
P/E ratio 2024 *
-5.49 x
P/E ratio 2025 *
-4.88 x
Employees 56
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.16%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Akero Therapeutics, Inc.

1 day+1.56%
1 week-4.48%
Current month-12.19%
1 month-22.07%
3 months-1.16%
6 months+50.99%
Current year-5.01%
More quotes
1 week
21.26
Extreme 21.26
23.76
1 month
21.26
Extreme 21.26
28.24
Current year
15.32
Extreme 15.32
37.00
1 year
11.25
Extreme 11.25
58.38
3 years
7.52
Extreme 7.52
58.38
5 years
7.52
Extreme 7.52
58.38
10 years
7.52
Extreme 7.52
58.38
More quotes
Managers TitleAgeSince
Founder 54 17-03-31
Founder 70 17-03-31
Chief Executive Officer 57 18-08-31
Members of the board TitleAgeSince
Director/Board Member 63 16-12-31
Director/Board Member 59 19-04-22
Chairman 57 18-10-31
More insiders
Date Price Change Volume
24-04-12 22.18 +1.56% 866,406
24-04-11 21.84 -0.27% 626,703
24-04-10 21.9 -7.75% 817,247
24-04-09 23.74 +2.64% 465,327
24-04-08 23.13 -0.39% 352,016

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT

More quotes
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.18 USD
Average target price
50 USD
Spread / Average Target
+125.43%
Consensus